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Over the last years, new molecular prognostic and predictive markers in malignant
tumours have been daily proposed by basic researchers; their clinical application have con-
sistently contributed to increase the Pathology Services workload; immunohistochemistry
often surrogates other more sophisticated biotechnologies with acceptable results
although in several cases molecular techniques look preferable. Breast cancer is a model
widely studied and effort is made to improve therapeutic results. Conventional macro-
microscopic parameters, evaluation by immunohistochemistry of Ki 67, ER, PR and HER2
status represent consolidated and standardised prognostic factors; ER, PR and HER2 status
are also validated predictive markers; for HER2 status, in borderline cases, hybridisation
in situ technologies, such as FISH, improve the definition of result.
In future, other molecular markers for new targeted therapeutic approaches will be prob-
ably consolidated; the more promising of them are VEGF, Topoisomerase-alpha II, PTEN and
other members of c-erbB (HER) family such as HER1 (EGFR) and HER 3.
 2008 Elsevier Ltd. All rights reserved.It is widely known that breast cancer is a heterogeneous HER2 status by immunohistochemistry are universally vali-disease embracing several different phenotypes with consis-
tently different biological characteristics.
In order to plan specific therapies for breast cancer as well
as other tumours, the pathologist plays a key role in tight
relationship with the oncologist. Recently, new classificative
approaches prevailing based on genetic more than morpho-
logical and immunohistochemical profiles have been pro-
posed; nevertheless, traditional morphological classification
continues to be applied and the status of ER, PR and HER2
(c-erb2) are currently the only prognostic markers validated
as predictive to therapy response.1–4
Other accepted prognostic markers are represented by tra-
ditional morphological findings such as tumour size, grade,
lymphovascular invasion, lymph nodes status and Ki 67
(Mib1) evaluation by immunohistochemistry.5,6
At present, procedures to carry out, on each breast cancer,
Estrogen Receptor alpha (ER), Progesteron Receptor (PR) ander Ltd. All rights reserved
pi).dated; Fluorescence in situ hybridisation (FISH), Chromogenic
in situ hybridisation (CISH) and Silver in situ hybridisation
(SISH) being alternative accepted methods.7,8
Immunohistochemistry is the standard method for deter-
mining receptor status of both ER and PR. According to inter-
national guidelines, standard criteria for pre-analytical and
analytical phases should be established and rigorously con-
trolled by intra- and interlaboratory quality control pro-
grammes. Any level of reactivity has to be reported for both
receptors since only tumours with no evidence of reactivity
are considered non-responsive to endocrine therapy. It is to
remark that the immunoreactivity for ER and PR is only nucle-
ar. A popular score, largely diffused in Pathology laboratories,
is the Allred score that, ranging from 0 to 5, evaluates the
intensity of immunoreactivity and the proportion of stained
nuclei.9
The Human epidermal growth factor receptor 2 (HER2) is a
member of the epidermal growth factor receptor family. The
oncogene HER2 is located on chromosome 17q21; its amplifi-
cation leads to the overexpression of the transmembrane.
2 E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 1 –3protein in about 20–25% of breast cancer and represents an
adverse prognostic factor associated with high-grade tu-
mours, lymph node metastases and higher rate of mortality.
HER2 status is also a specific predictive marker to response
to trastuzumab, a humanised monoclonal antibody that, val-
idated by several wide studies, has demonstrated to improve
time to progression and overall survival of breast advanced
cancer and, more recently, also to reduce risk of recurrence
and mortality in adjuvant setting for early breast cancer. Cur-
rent largely diffuse protocols imply the detection of HER2 pro-
tein expression by immunohistochemistry (several validated
antibodies are available); a score graded from 0 to 3+ on the
basis of intensity of the chromatic signal and the percentage
of positive cell, evaluating only the membrane reactivity
(chicken wire pattern) is largely used. Cases from 0 to 1+ are
considered negative, score 3+ positive and eligible for trast-
uzumab therapy. Borderline cases (2+) have to be tested for
gene amplification by FISH or (alternatively) CISH or more
recently SISH.10
On the basis of gene microarrays technique, several sub-
types of breast carcinomas have been individuated and spe-
cifically a luminal type subclassifiable in luminal type A,
characterised by the highest expression of ER alpha gene
and the best prognosis, luminal B and luminal C with a lower
level of expression of ER alpha gene and a poorer prognosis, a
basal cell-like type characterised by the absence of expression
of hormone receptors and HER2 and representing a good
number of cases of the so-called ‘triple negative immunophe-
notype’ and a HER2 overexpressing type; basal cell-like type
and HER2 overexpressing type have the worst prognosis.11–13
It is absolutely evident that this scheme is strongly sugges-
tive and, on the basis of current knowledge and available
drugs, also the best one to classify breast tumours on the clin-
ical standpoint; great effort is developing also to correlate
morphological conventional histotypes with these gene tu-
mour profiles, and some interesting result has been reached.
Moreover, new scenarios are emerging in order to individ-
uate predictive markers for new or integrated therapies; for
example, cases showing resistance to trastuzumab therapy
have evidenced the need to select other markers.
In the future, promising predictive markers for breast car-
cinoma are VEGF, Topoisomerase II-alpha, PTEN and other
members of EGFR family.
VEGF (Vascular endothelial growth factor) is the main pro-
angiogenic factor that also regulates the permeability of
endothelial cells; an overexpression of VEGF in several tu-
mours, including breast cancer, is associated with a poor
prognosis and preliminary studies have demonstrated the
efficacy of bevacizumab, a recombinant humanised monoclo-
nal antibody developed against VEGF that binds to soluble
VEGF, to prevent receptor binding and inhibit endothelial cell
proliferation and vessel formation.14
Topoisomerase II-alpha (TOP2A) gene amplification is a
potentially useful predictive marker of responsiveness to
anthracycline-containing chemotherapy. This gene is fre-
quently co-amplified with HER2 since it is located in the prox-
imity of HER2 in the 17qchromosome. Many studies have
demonstrated that TOP2A amplification represents a useful
marker to predict the responsiveness to anthracycline-based
therapy, also in breast cancer.15PTEN (Phosphatase and tensin homologue deleted on
chromosome 10) is a tumour suppressor gene frequently
down-regulated in breast carcinoma. PTEN is probably
involved in the mechanisms of trastuzumab resistance, loss
of function of PTEN, negative regulator of phosphatidylinosi-
tol 3-kinase/Akt pathway, implies a decreased sensitivity to
trastuzumab.16,17
EGFR family. Targeted therapies to both ErbB1 (EGFR, HER1)
and ErbB2 (HER2) are advanced in clinical trials.18 In addition,
an increasing role of ErbB3 in breast cancer is emerging. ErbB3
is frequently overexpressed in breast cancer and the coex-
pression with HER2 is considered a poor prognostic indicator.
ErbB3 has also been involved in the development of resistance
to antiestrogens. It has been also postulated that ErbB3 could
be a partner for ErbB2 (HER2) in promoting breast tumour cell
proliferation, by a heterodimer formation.19,20 So far little is
known about the role of ErbB4 and its possible clinical rele-
vance.21 In any case, an evaluation of HER1 and HER3 overex-
pression will be useful in the future. A strategy for studying
prognostic and predictive profiles of breast tumours has been
developed using smaller sets of genes. Although results are
very interesting, we are probably far to introduce similar tech-
nology in diagnostic routine since, so far, the real superiority
of this test remains unproven but it is considerably
expensive.22
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